A Phase II Randomized, Double-blinded, Multicenter Asian Study Investigating the Combination of Transcatheter Arterial Chemoembolization (TACE) and Oral Everolimus (RAD001, Afinitor) in Localised Unresectable Hepatocellular Carcinoma (HCC) - The TRACER Study

Trial Profile

A Phase II Randomized, Double-blinded, Multicenter Asian Study Investigating the Combination of Transcatheter Arterial Chemoembolization (TACE) and Oral Everolimus (RAD001, Afinitor) in Localised Unresectable Hepatocellular Carcinoma (HCC) - The TRACER Study

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 May 2017

At a glance

  • Drugs Everolimus (Primary) ; Antineoplastics
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms TRACER
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 13 Apr 2017 Status changed from completed to discontinued.
    • 05 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 16 Apr 2015 Planned End Date changed from 1 Mar 2015 to 1 Jun 2015,as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top